11 research outputs found
Supplemental Figure 3 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 3. GIST PDGFRA D842V PDXs are not sensitive to crenolanib.</p
Supplemental Figure 1 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 1.</p
Supplemental Figure 2 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 2. GIST PDGFRA D842V PDXs are not sensitive to imatinib.</p
Supplemental Figure 6 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 6.Cell survival of GIST T1 cells treated with imatinib or avapritinib for 72h in complete media.Each data point represents an average of 10 wells.</p
Supplemental Figure 5 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 5.Short term culture of cells derived from PDGFRA D842V PDXs are tumor cells.</p
Supplemental Figure 8 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 8.Relative MYLK mRNA expression by qPCR in GIST PDGFRA D842V PDXs treated with vehicle(Veh) or imatinib (IM) for 2 weeks.</p
Supplemental Figure 7 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 7.</p
Supplemental Figure 4 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>PDGFRA D842V</i>-Mutant Gastrointestinal Stromal Tumor
Supplemental Figure 4.</p
Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Normalized Tryptophan Concentrate Over Time</p
Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Representativeness of study participants.</p